Loading clinical trials...
Loading clinical trials...
AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH CD22-POSTIVE NON-HODGKIN'S LYMPHOMA
Conditions
Interventions
inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone
inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Locations
28
United States
Davis Cancer Pavillion and Shands Medical Plaza
Gainesville, Florida, United States
Shands Cancer Hospital At The University Of Florida
Gainesville, Florida, United States
Shands Hospital at the University of Florida
Gainesville, Florida, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Northwest Medical Specialties, PLLC
Federal Way, Washington, United States
Start Date
March 1, 2010
Primary Completion Date
July 1, 2013
Completion Date
March 1, 2014
Last Updated
August 2, 2019
NCT04161248
NCT06528301
NCT06008691
NCT05940272
NCT06534437
NCT06954805
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions